Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Baden – page 57

865 clinical trials in Baden, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Baden at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Baden

Open in trial search

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Rheumatoid arthritis

Not recruiting

Study on Burfiralimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Burfiralimab
  • Sponsor:Immunemed Inc.

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Myopia

Not recruiting

Study on the Safety and Effectiveness of SYD-101 Eye Drops with Atropine Sulfate Monohydrate for Treating Myopia in Children

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Atropine Sulfate Monohydrate
  • Sponsor:Sydnexis Inc.

Study of Sotorasib Alone and Combined with Pembrolizumab in Adult Patients with Advanced Solid Tumors Having KRAS p.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Amgen Inc.

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Baden

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer evaluating personalized treatment approaches using targeted therapies.

  • Adjuvant therapy optimization
  • Personalized treatment strategies
  • Novel drug combinations

Studies aim to improve survival rates through dynamic marker-adjusted therapeutic approaches.

02 Triple-Negative Breast Cancer

Research examining neoadjuvant treatment options for patients with early-stage triple-negative breast cancer, comparing innovative therapeutic combinations.

  • Treatment response assessment
  • Immunotherapy combinations
  • Survival outcome evaluation

Focus on improving treatment efficacy in low-risk recurrence patients.

03 Ovarian Cancer Studies

Advanced research on HRD-positive high-grade ovarian cancer, investigating optimized treatment durations and maintenance therapy approaches.

  • Chemotherapy optimization
  • Maintenance therapy evaluation
  • Recurrence prevention strategies

Emphasis on improving outcomes for patients with no residual tumor after debulking surgery.

04 Leukemia Research

Groundbreaking studies in chronic lymphocytic leukemia (CLL) examining novel drug combinations for high-risk patients.

  • Targeted therapy combinations
  • High-risk patient treatment
  • Disease progression prevention

Investigation of innovative triple-combination therapies for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.